Clinical Trials Logo

Metabolomics clinical trials

View clinical trials related to Metabolomics.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06102655 Recruiting - Clinical trials for Traditional Chinese Medicine

Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics

JJGS and POI
Start date: July 24, 2023
Phase: Early Phase 1
Study type: Interventional

1. Identify differential metabolites in POI patients. 2. Analysis of differential metabolites and their involved mechanism pathways.

NCT ID: NCT06094439 Recruiting - Metabolomics Clinical Trials

Targeted Metabolomics and Spent Embryo Culture Medium

Start date: September 1, 2023
Phase:
Study type: Observational

More than 8 million babies have been born through in vitro fertilization (IVF). Non-invasive observation of embryos in vitro to better understand their development is becoming increasingly important. Morphology has been used as standard from the beginning, but has the disadvantage of subjectivity. Now the emphasis in basic and clinical research is on developing rapid, quantitative, non-invasive tests. Hence comes the idea of metabolic profiling of spent embryo culture medium (SECM) as a biomarker. This could be useful for understanding and improving the nutritional environment of oocytes and embryos. The goal of our study is to determine metabolic profiles of the SECM in combination with morphological assessments to better understand the nutritional requirements of the embryo. The goal would be to optimize media specifically, depending on patient and embryo characteristics ("personalized medicine") ("the embryo in vitro as patient").

NCT ID: NCT06073470 Recruiting - Metabolomics Clinical Trials

Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD

Start date: January 1, 2024
Phase:
Study type: Observational

To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.

NCT ID: NCT05891886 Recruiting - Pulmonary Embolism Clinical Trials

Supplemental Oxygen in Pulmonary Embolism (SO-PE)

SO-PE
Start date: October 1, 2023
Phase: Early Phase 1
Study type: Interventional

A study of how supplemental oxygen helps patients with acute pulmonary embolism (PE). Hypothesis: Oxygen affects right ventricular dysfunction (RVD) in patients with acute pulmonary embolism (PE) primarily by relieving hypoxic pulmonary vasoconstriction and reducing pulmonary pressure (PA) pressure, and that this process is metabolically driven.

NCT ID: NCT05616585 Recruiting - Diet, Healthy Clinical Trials

Dietary Biomarkers Intervention Core

Start date: February 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this controlled feeding trial is to establish an Intervention Core, equipped to perform tightly controlled pharmacokinetic (PK) and dose-response (DR) feeding studies. This research is a two-component pharmacokinetic and pharmacodynamic cross-over dietary feeding trial. - In the PK study, eight foods will be tested, each on a single day, and the design is crossover. - In the DR, the effects of 10 foods will be compared to each other in a randomized, parallel-group design, and the dose-effect of each of the 10 foods will be determined in a randomized, crossover design.

NCT ID: NCT05582824 Recruiting - Metabolism Clinical Trials

Lactate Metabolism in the Hypoperfused Critically Ill

Start date: September 15, 2022
Phase:
Study type: Observational

Investigating lactate metabolism in critically ill patients whom are hypoperfused by preforming metabolomics via liquid chromatography-mass spectrometry.

NCT ID: NCT05243173 Recruiting - Clinical trials for Renal Cell Carcinoma

Biomarkers of Response to Systemic Treatments in FH-deficient RCC

Start date: May 25, 2022
Phase:
Study type: Observational

Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare subtype of RCC characterized by germline/somatic mutation of the fumarate hydratase (FH) gene, and is an extremely aggressive tumor, with a propensity to disseminate early even in the setting of a small primary tumor. Affected individuals or individuals suspected of having a germline FH will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation. Genetic linkage studies may be performed in situations in which the genetic basis of the disorder has not been elucidated.

NCT ID: NCT05205187 Recruiting - Stomach Neoplasms Clinical Trials

Gut Microbiota and Metabonomics

MBS
Start date: February 28, 2022
Phase:
Study type: Observational [Patient Registry]

To evaluate the correlation between gut microbiota and metabolites in Borrmann type IV gastric cancer; To find the effects of microflora and metabolites on target organs; To detect the mechanism of key flora and metabolite by in vitro and in vivo experiments; To construct models of gut microbiota and metabonomics by machine learning.

NCT ID: NCT04992104 Recruiting - Pregnancy Related Clinical Trials

Microbiome and Malnutrition in Pregnancy

MMIP
Start date: February 22, 2023
Phase:
Study type: Observational

This study is being conducted to investigate how a mother's nutritional status and her gut microbiome during pregnancy contribute to the birth outcomes and health of her baby. The gut microbiome is the totality of microorganisms (e.g. bacteria, viruses, fungi) living in the gastrointestinal tract. This study will focus on pregnant women, 24 years and younger living in the Toronto and greater Toronto area. The focus is on younger women due to their vulnerability to undernutrition. Pregnant participants, and upon delivery, their newborns will be followed throughout pregnancy and for a year afterwards. Throughout this period, the investigators will collect stool samples, rectal swabs, blood samples, health assessments, nutritional and dietary assessments and birth/ labour details. The goal is to define the relationship between a mother's nutritional status and her microbiome dynamics during pregnancy and how they contribute to the birth outcomes and growth of her newborn. With the hypothesis that alterations of the microbiota in the maternal gut (dysbiosis) exacerbated by nutritional status or pathogen exposure during pregnancy, impacts weight gain because of impaired nutrient absorption, leading to corresponding negative birth outcomes.

NCT ID: NCT04832100 Recruiting - Pain Clinical Trials

Bio-significance of LPC16:0 in Fibromyalgia

Start date: August 1, 2017
Phase:
Study type: Observational

Fibromyalgia (FM) is a very common but mysterious pain disorder characterized by chronic widespread muscular pain. Fatigue, anxiety and depression are common comorbidities. The syndrome is commonly associated with several symptoms, including fatigue, sleeping disturbance, cognitive impairment, and comorbid pain syndrome, especially irritable bowel symptoms and temporomandibular disease. Anxiety and depression are common psychiatric co-morbidies. Daily stress is believed to trigger or aggravate pain conditions. These symptoms can markedly affect patients' quality of life, and even lead to disability. So far, the etiology and pathogenesis are largely unknown, and diagnostic biomarkers and curative treatment remain to be developed. Recent technological advances enable scientists to explore mechanisms by genetic, transcriptomic, proteomic, and metabolomic researches. However, no definitive result has been concluded for clinical practice so far. In this study, the investigators use tailored questionnaires to evaluate fibromyalgia and associated symptoms, including numeric rating scale for soreness, widespread soreness index, Fibromyalgia impact questionnaire, Hospital Anxiety and Depression Scale, and perceived stress scale. The investigators also use metabolomics and lipidomic approach to probe the potential pathophysiology of fibromyalgia. In our prior translation research (PMID: 32907805), the investigators found that excessive LPC16:0 resulting from lipid oxidization inflicts psychological stress-induced chronic non-inflammatory pain via activating ASIC3. In this content, our prior translational research identified a potential nociceptive ligand that causes fibromyalgia symptoms, which is likely to function as biomarkers for diagnosis or disease monitor. In the current clinical investigation, the investigators aim to reversely translate the novel findings in animal studies and validate the bio-significance of LPC16:0 for fibromyalgia with clinical approaches.